SCHEMBL12470302

SCHEMBL12470302

CCCC(Oc1ccc(-n2cc(C(F)(F)F)c(C)n2)cc1)c1ccc(C(=O)NCCC(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCGR P47871 11/20 1.00
GCG P01275 11/20 0.78
GLP1R P43220 1/20 0.69
GIPR P48546 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11962669 0.89 GCG (0.84) GCGRGCG
SCHEMBL11962693 0.89 GCGR (0.79) GCGRGCGGLP1RGIPR
SCHEMBL11962655 0.88 GCG (0.82) GCGRGCG
SCHEMBL11962653 0.87 GCG (1.00) GCGRGCG
SCHEMBL11962691 0.86 GCGR (0.76) GCGRGCGGLP1RGIPR
SCHEMBL11900201 0.85 GCGR (1.00) GCGRGCGGLP1RGIPR
SCHEMBL11899819 0.85 GCGR (1.00) GCGRGCGGLP1RGIPR
SCHEMBL11899818 0.85 GCGR (1.00) GCGRGCGGLP1RGIPR
SCHEMBL11962694 0.84 GCGR (0.73) GCGRGCGGLP1RGIPR
SCHEMBL11962660 0.83 GCG (0.78) GCGRGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2673260-A1 GLUCAGON RECEPTOR MODULATOR Pfizer Inc (US) 2013-12-18 EP claimed
WO-2012107850-A1 GLUCAGON RECEPTOR MODULATOR PFIZER INC. (US) 2012-08-16 WO claimed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
US-9452999-B2 Glucagon receptor modulators PFIZER INC. (US) 2016-09-27 US disclosed
EP-2673260-B1 GLUCAGON RECEPTOR MODULATOR PFIZER (US) 2016-08-17 EP disclosed
EP-2673260-B1 GLUCAGON RECEPTOR MODULATOR PFIZER (US) 2016-08-17 EP disclosed
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2015-09-24 US disclosed
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2015-09-24 US disclosed
US-9073871-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-07-07 US disclosed
US-9073871-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-07-07 US disclosed
US-9073871-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-07-07 US disclosed
US-20140371467-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2014-12-18 US disclosed
US-20140371467-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2014-12-18 US disclosed
US-20140371467-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2014-12-18 US disclosed
EP-2673260-A1 GLUCAGON RECEPTOR MODULATOR Pfizer Inc (US) 2013-12-18 EP disclosed
WO-2012107850-A1 GLUCAGON RECEPTOR MODULATOR PFIZER INC. (US) 2012-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266859-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885
US-20140371467-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.